Drugs that contain Sofosbuvir

1. Drug name - SOVALDI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8334270 GILEAD SCIENCES INC NA
Mar, 2028

(5 years from now)

US8580765 GILEAD SCIENCES INC NA
Mar, 2028

(5 years from now)

US9085573 GILEAD SCIENCES INC NA
Mar, 2028

(5 years from now)

US7964580 GILEAD SCIENCES INC NA
Mar, 2029

(6 years from now)

US8633309 GILEAD SCIENCES INC Nucleoside phosphoramidates
Mar, 2029

(6 years from now)

US9284342 GILEAD SCIENCES INC Nucleoside phosphoramidates
Sep, 2030

(7 years from now)

US8618076 GILEAD SCIENCES INC Nucleoside phosphoramidates
Dec, 2030

(8 years from now)

CN102906102A GILEAD SCIENCES INC Stereoselective Synthesis Of Phosphorus-Containing Active Matter
Nov, 2015

(6 years ago)

CN104292256A GILEAD SCIENCES INC N - [(2 ' R) -2 '--2 '--2 ' - Methyl-Beta-Phenyl - -5 ' - Uridine Acyl] -L - Alanine 1-Methyl Ethyl Ester And Preparation Method Thereof
Nov, 2018

(3 years ago)

CN105198949A GILEAD SCIENCES INC N-[(2 ' R)-2 '--2 '-Fluorin-2 '-De-Oxide Methyl-[Beta]-Phenyl-5 '-Uridine Acyl]-L-Alanine 1-Methyl Ethyl Ester And Its Preparation Method
Dec, 2019

(2 years ago)

CN105085592B GILEAD SCIENCES INC N - [(2 ' R) - 2 ' - Deoxy-2 ' - Fluorine-2 ' - Methyl-Beta-Phenyl-5 ' - Uridine Acyl] -L - Lactamine 1-Methyl Ethyl Ester And Its Preparation Method
May, 2030

(7 years from now)

CN102459299B GILEAD SCIENCES INC N- [ (2 ' R) -2 ' -Deoxy-2 ' -Fluoro-2 ' -Methyl-P-Phenyl-5 ' -Uridylyl] -L-Alanine 1-Methylethyl Ester And Process For Its Production
May, 2030

(7 years from now)

CN105085592A GILEAD SCIENCES INC N-[(2 ' R)-2 '--2 '-Fluorin-2 '-De-Oxide Methyl-[Beta]-Phenyl-5 '-Uridine Acyl]-L-Alanine 1-Methyl Ethyl Ester And Preparation Method Thereof
May, 2030

(7 years from now)

CN102459299A GILEAD SCIENCES INC N- [ (2 ' R) -2 ' -Deoxy-2 ' - Fluoro-2'-Methyl-P-Phenyl-5 ' -Uridylyl] -L-Alanine-1-Methylethyl Ester Process For Its Production
May, 2030

(7 years from now)

CN104017020B GILEAD SCIENCES INC Nucleoside Phosphoramidate
Mar, 2031

(8 years from now)

CN104017020A GILEAD SCIENCES INC Stereoselective Synthesis Of Phosphorus Containing Actives
Mar, 2031

(8 years from now)

IN346815B GILEAD SCIENCES INC N-[ (2&Amp;Apos;R) -2&Amp;Apos; Deoxy-2&Amp;Apos;- Fluoro-2&Amp;Apos;-Methyl-Pphenyl- 5&Amp;Apos;-Uridylyl] -L-Alanine 1- Methylethyl Ester And Process For Its Production
May, 2030

(7 years from now)

EP2203462B1 GILEAD SCIENCES INC Nucleoside Phosphoramidate Prodrugs
Jul, 2020

(2 years ago)

EP2203462A2 GILEAD SCIENCES INC Nucleoside Phosphoramidate Prodrugs
Jul, 2020

(2 years ago)

EP2826784B1 GILEAD SCIENCES INC Composition Comprising A Hcv Ns3 Protease Inhibitor And A Phosphoramidate Prodrug Of 2'-Deoxy-2'-Fluoro-2'-C-Methyluridine Nucleoside
Mar, 2028

(5 years from now)

EP2826784A1 GILEAD SCIENCES INC Composition Comprising A Hcv Ns3 Protease Inhibitor And A Phosphoramidate Prodrug Of 2'-Deoxy-2'-Fluoro-2'-C-Methyluridine Nucleoside
Mar, 2028

(5 years from now)

EP2913337A1 GILEAD SCIENCES INC Process For The Production Of Sofosbuvir
May, 2030

(7 years from now)

EP2432792A1 GILEAD SCIENCES INC And Process For The Preparation Of N-[(2'R)-2'-Deoxy-2'-Fluoro-2'-Methyl-P-Phenyl-5'-Uridylyl]-L-Alanine 1-Methylethyl Ester
May, 2030

(7 years from now)

EP3321275B1 GILEAD SCIENCES INC Crystalline Form Of Sofosbuvir
May, 2030

(7 years from now)

EP3321275A1 GILEAD SCIENCES INC Crystalline Form Of Sofosbuvir
May, 2030

(7 years from now)

EP2432792B1 GILEAD SCIENCES INC And Process For The Preparation Of N-[(2'R)-2'-Deoxy-2'-Fluoro-2'-Methyl-P-Phenyl-5'-Uridylyl]-L-Alanine 1-Methylethyl Ester
May, 2030

(7 years from now)

EP2913337B1 GILEAD SCIENCES INC Process For The Production Of Sofosbuvir
May, 2030

(7 years from now)

EP2752422A1 GILEAD SCIENCES INC Stereoselective Synthesis Of Phosphorus Containing Actives
Mar, 2031

(8 years from now)

EP3290428B1 GILEAD SCIENCES INC Tablet Comprising Crystalline (S)-Isopropyl 2-(((S)-(((2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-Dihydropyrimidin-1 (2H)-Yl)-4-Fluoro-3-Hydroxy-4-Methyltetrahydrofuran-2-Yl)Methoxy)(Phenoxy)Phosphoryl)Amino)Propanoate
Mar, 2031

(8 years from now)

EP2552930B1 GILEAD SCIENCES INC Crystalline (S)-Isopropyl 2-(((S)-(((2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-Dihydropyrimidin-1-(2H)-Yl)-4-Fluoro-3-Hydroxy-4-Methyltetrahydrofuran-2-Yl)Methoxy)(Phenoxy)Phosphoryl)Amino)Propanoate
Mar, 2031

(8 years from now)

EP2552931A2 GILEAD SCIENCES INC Stereoselective Synthesis Of Phosphorus Containing Actives
Mar, 2031

(8 years from now)

EP2552931B1 GILEAD SCIENCES INC Stereoselective Synthesis Of Phosphorus Containing Actives
Mar, 2031

(8 years from now)

EP2609923A2 GILEAD SCIENCES INC Process For The Crystallisation Of (S)-Isopropyl 2-(((S)-(Perfluorophenoxy)(Phenoxy)Phosphoryl)Amino)Propanoate
Mar, 2031

(8 years from now)

EP2552930A2 GILEAD SCIENCES INC Crystalline (S)-Isopropyl 2-(((S)-(((2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-Dihydropyrimidin-1-(2H)-Yl)-4-Fluoro-3-Hydroxy-4-Methyltetrahydrofuran-2-Yl)Methoxy)(Phenoxy)Phosphoryl)Amino)Propanoate
Mar, 2031

(8 years from now)

EP2609923A3 GILEAD SCIENCES INC Nucleoside Phosphoramidates
Mar, 2031

(8 years from now)

EP3290428A1 GILEAD SCIENCES INC Tablet Comprising Crystalline (S)-Isopropyl 2-(((S)-(((2R,3R,4R,5R)-5-(2,4-Dioxo-3,4-Dihydropyrimidin-1 (2H)-Yl)-4-Fluoro-3-Hydroxy-4-Methyltetrahydrofuran-2-Yl)Methoxy)(Phenoxy)Phosphoryl)Amino)Propanoate
Mar, 2031

(8 years from now)

EP2752422B1 GILEAD SCIENCES INC Stereoselective Synthesis Of Phosphorus Containing Actives
Mar, 2031

(8 years from now)

EP2609923B1 GILEAD SCIENCES INC Process For The Crystallisation Of (S)-Isopropyl 2-(((S)-(Perfluorophenoxy)(Phenoxy)Phosphoryl)Amino)Propanoate
Mar, 2031

(8 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8580765

(Pediatric)

GILEAD SCIENCES INC NA Sep, 2028

(5 years from now)

US8334270

(Pediatric)

GILEAD SCIENCES INC NA Sep, 2028

(5 years from now)

US9085573

(Pediatric)

GILEAD SCIENCES INC NA Sep, 2028

(5 years from now)

US8889159 GILEAD SCIENCES INC Compositions and methods for treating hepatitis C virus Mar, 2029

(6 years from now)

US9549941 GILEAD SCIENCES INC Compositions and methods for treating hepatitis C virus Mar, 2029

(6 years from now)

US7964580

(Pediatric)

GILEAD SCIENCES INC NA Sep, 2029

(6 years from now)

US8633309

(Pediatric)

GILEAD SCIENCES INC Nucleoside phosphoramidates Sep, 2029

(6 years from now)

US8889159

(Pediatric)

GILEAD SCIENCES INC Compositions and methods for treating hepatitis C virus Sep, 2029

(6 years from now)

US9549941

(Pediatric)

GILEAD SCIENCES INC Compositions and methods for treating hepatitis C virus Sep, 2029

(6 years from now)

US9284342

(Pediatric)

GILEAD SCIENCES INC Nucleoside phosphoramidates Mar, 2031

(8 years from now)

US8618076

(Pediatric)

GILEAD SCIENCES INC Nucleoside phosphoramidates Jun, 2031

(8 years from now)

Treatment: For the treatment of hepatitis c; For the treatment of genotype 1, 2, 3 or 4 chronic hepatitis c virus (hcv) infection as a component of a combination antiviral treatment regimen with ribavirin

Dosage: PELLETS;ORAL

More Information on Dosage
Strength Dosage Availability
150MG/PACKET PELLETS;ORAL Prescription
200MG/PACKET PELLETS;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.